ScholarLens Back to search
2013•Formulary ENewsRequires access

FDA approves first anti-IL-12/23 psoriatic arthritis drug

Formulary staff

Open publisher page 0 citations

Abstract

FDA has approved ustekinumab (Stelara, Janssen Biotech) alone or in combination with methotrexate for active psoriatic arthritis in adult patients aged 18 years and older.

About this research paper

What this paper is about

FDA has approved ustekinumab (Stelara, Janssen Biotech) alone or in combination with methotrexate for active psoriatic arthritis in adult patients aged 18 years and older.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

FDA has approved ustekinumab (Stelara, Janssen Biotech) alone or in combination with methotrexate for active psoriatic arthritis in adult patients aged 18 years and older.

Key concepts: Medicine, Psoriatic arthritis, Drug, Dermatology, Pharmacology, Psoriasis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
FDA approves first anti-IL-12/23 psoriatic arthritis drug — Research Paper | ScholarLens